Dihydropyrimidine dehydrogenase deficiency in an Indian population

  • Muhammad Wasif Saif
  • Lori Mattison
  • Tom Carollo
  • Hany Ezzeldin
  • Robert B. Diasio
Original Article


Background: Dihydropyrimidine dehydrogenase (DPD) deficiency is prevalent in 3–5% of the Caucasian population; however, the frequency of this pharmacogenetic syndrome in the Indian population and other racial and ethnic groups remains to be elucidated. Patients and methods: We describe an Indian patient who presented to clinic for the treatment of gastric adenocarcinoma with 5-flurouracil (5-FU) therapy who subsequently was diagnosed with DPD deficiency by using the peripheral blood mononuclear cell (PBMC) DPD radioassay. This observation prompted us to examine the data generated from healthy (cancer-free) Indian subjects who were enrolled in a large population study to determine the sensitivity and specificity of the uracil breath test (UraBT) in the detection of DPD deficiency. Thirteen Indian subjects performed the UraBT. UraBT results were confirmed by PBMC DPD radioassay. Results: The Indian cancer patient demonstrated reduced DPD activity (0.11 nmol/min/mg protein) and severe 5-FU toxicities commonly associated with DPD deficiency. Of the 13 Indian subjects [ten men and three women; mean age, 26 years (range: 21–31 years)] enrolled in the UraBT, 12 Indian subjects demonstrated UraBT breath profiles and PBMC DPD activity within the normal range; one Indian subject demonstrated a reduced breath profile and partial DPD deficiency. Conclusions: DPD deficiency is a pharmacogenetic syndrome which is also present in the Indian population. If undiagnosed, the DPD deficiency can lead to death. Future epidemiological studies would be helpful to determine the prevalence of DPD deficiency among racial and ethnic groups, allowing for the optimization of 5-FU chemotherapy.


Dihydropyrimidine dehydrogenase (DPD) enzyme 5-Fluoruracil (5-FU) Fluoropyrimidine DPD deficiency Indian Race 



This work was supported in part by NIH grant CA 62164.


  1. 1.
    Meta-analysis Group in Cancer (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16(11):3537–3541Google Scholar
  2. 2.
    Van Kuilenburg AB et al (2002) Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer 101(3):253–258Google Scholar
  3. 3.
    Canellakis ES (1956) Pyrimidine metabolism. I. Enzymatic pathways of uracil and thymine degradation. J Biol Chem 221(1):315–322PubMedGoogle Scholar
  4. 4.
    Daher GC, Harris BE, Diasio RB (1990) Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther 48(2):189–222CrossRefPubMedGoogle Scholar
  5. 5.
    Diasio RB, Beavers TL, Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81(1):47–51PubMedCrossRefGoogle Scholar
  6. 6.
    Diasio RB, Johnson MR (1999) Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 5(10):2672–2673PubMedGoogle Scholar
  7. 7.
    Harris BE, Carpenter JT, Diasio RB (1991) Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 68(3):499–501PubMedCrossRefGoogle Scholar
  8. 8.
    Morrison GB et al (1997) Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. Oncol Nurs Forum 24(1):83–88PubMedGoogle Scholar
  9. 9.
    Ezzeldin H, Diasio R (2004) Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 4(3):181–189PubMedCrossRefGoogle Scholar
  10. 10.
    Johnson MR, Wang K, Diasio RB (2002) Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 8(3):768–774PubMedGoogle Scholar
  11. 11.
    Etienne MC et al (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12(11):2248–2253PubMedGoogle Scholar
  12. 12.
    Lu Z et al (1998) Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 4(2):325–329PubMedGoogle Scholar
  13. 13.
    Mattison LK et al (2005) Evidence for increased incidence of dihydropyrimidine dehydrogenase (DPD) deficiency in African Americans compared to Caucasians. Proceedings of the 2005 ASCO Annual Meeting 2005:2004Google Scholar
  14. 14.
    Johnson MR et al (1997) Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl 696(2):183–191CrossRefPubMedGoogle Scholar
  15. 15.
    Mattison LK et al (2004) Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res 10(8):2652–2658CrossRefPubMedGoogle Scholar
  16. 16.
    Macdonald JS et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10):725–730CrossRefPubMedGoogle Scholar
  17. 17.
    Harris BE et al (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50(1):197–201PubMedGoogle Scholar
  18. 18.
    Meretek Diagnostics I (2002) In: Meretek UBiT-IR300: 13CO2 urea breath analyzer instruction manual. Lafayette, CO, Meretek Diagnostics, pp A1–A2Google Scholar
  19. 19.
    Amarri S, Weaver LT (1995) 13C-breath tests to measure fat and carbohydrate digestion in clincial practice. Clin Nutr (14):149–154CrossRefGoogle Scholar
  20. 20.
    Lu Z, Zhang R, Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53(22):5433–5438PubMedGoogle Scholar
  21. 21.
    Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254CrossRefPubMedGoogle Scholar
  22. 22.
    Ezzeldin H et al (2002) A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal Biochem 306(1):63–73CrossRefPubMedGoogle Scholar
  23. 23.
    Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16(4):215–237PubMedCrossRefGoogle Scholar
  24. 24.
    Johnson MR, Diasio RB (2001) Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 41:151–157CrossRefPubMedGoogle Scholar
  25. 25.
    van Kuilenburg AB et al (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6(12):4705–4712PubMedGoogle Scholar
  26. 26.
    Lu ZH, Zhang R, Diasio RB (1992) Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem 267(24):17102–17109PubMedGoogle Scholar
  27. 27.
    Ezzeldin H et al (2003) Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin Cancer Res 9(8):3021–3028PubMedGoogle Scholar
  28. 28.
    Mattison LK, Soong R, Diasio RB (2002) Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 3(4):485–492CrossRefPubMedGoogle Scholar
  29. 29.
    Raida M et al (2001) Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res 7(9):2832–2839PubMedGoogle Scholar
  30. 30.
    Ezzeldin HH et al (2005) Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 11(24) (in press)Google Scholar
  31. 31.
    Collie-Duguid ES et al (2000) Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 10(3):217–223CrossRefPubMedGoogle Scholar
  32. 32.
    Hamdy SI et al (2002) Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 53(6):596–603CrossRefPubMedGoogle Scholar
  33. 33.
    Morsman JM et al (2000) Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations. Br J Clin Pharmacol 50(3):269–272CrossRefPubMedGoogle Scholar
  34. 34.
    Yamaguchi K et al (2001) Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil. Jpn J Cancer Res 92(3):337–342PubMedGoogle Scholar
  35. 35.
    Sohn DR, Cho MS, Chung PJ (1999) Dihydropyrimidine dehydrogenase activity in a Korean population. Ther Drug Monit 21(2):152–154CrossRefPubMedGoogle Scholar
  36. 36.
    Ridge SA et al (1998) Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol 46(2):151–156CrossRefPubMedGoogle Scholar
  37. 37.
    Gross E et al (2003) High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism. Int J Oncol 22(2):325–332PubMedGoogle Scholar
  38. 38.
    van Kuilenburg AB et al (2001) Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 7(5):1149–1153PubMedGoogle Scholar
  39. 39.
    Humerickhouse RA et al (1999) Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res 5(2):291–298PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Muhammad Wasif Saif
    • 1
    • 3
  • Lori Mattison
    • 2
  • Tom Carollo
    • 2
  • Hany Ezzeldin
    • 2
  • Robert B. Diasio
    • 2
  1. 1.Yale University School of MedicineNew HavenUSA
  2. 2.University of Alabama at BirminghamNew HavenUSA
  3. 3.Section of Medical OncologyYale University School of MedicineNew HavenUSA

Personalised recommendations